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ABSTRACT
Interleukin-34 (IL-34), a cytokine produced by a wide range of cells, binds to 
the macrophage colony-stimulating factor receptor (M-CSFR-1) and receptor-type 
protein-tyrosine phosphatase zeta (PTP-z) and controls myeloid cell differentiation, 
proliferation and survival. various types of cancers over-express IL-34 but the role 
of the cytokine in colorectal cancer (CRC) remains unknown. We here investigated 
the expression and functional role of IL-34 in CRC. A more pronounced expression 
of IL-34 was seen in CRC samples as compared to matched normal/benign colonic 
samples and this occurred at both RNA and protein level. Immunohistochemical 
analysis of CRC tissue samples showed that both cancer cells and lamina propria 
mononuclear cells over-expressed IL-34. Additionally, CRC cells expressed both 
M-CSFR-1 and PTP-z, thus suggesting that CRC cells can be responsive to IL-34. 
Indeed, stimulation of DLD-1 cancer cells with IL-34, but not with MSCF1, enhanced 
the cell proliferation and cell invasion without affecting cell survival. Analysis of 
intracellular signals underlying the mitogenic effect of IL-34 revealed that the cytokine 
enhanced activation of ERK1/2 and pharmacologic inhibition of ERK1/2 abrogated 
IL-34-driven cell proliferation. Consistently, IL-34 knockdown in HT-29 cells with a 
specific IL-34 antisense oligonucleotide reduced ERK1/2 activation, cell proliferation 
and enhanced the susceptibility of cells to Oxaliplatin-induced death. This is the first 
study showing up-regulation of IL-34 in CRC and suggesting a role for this cytokine 
in colon tumorigenesis.
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INTRODUCTION
Colorectal carcinoma (CRC) is one of the most 
common forms of malignancy and the second leading 
cause of cancer-related death in the Western world [1]. 
Chronic inflammation is an independent risk factor 
for the development of CRC [2]. Approximately 2% 
of CRC cases arise in patients with long-standing and 
extensive ulcerative colitis, one of the 2 major forms of 
inflammatory bowel diseases (IBD) in humans, while 
the majority of CRCs develops in individuals who are 
not affected by IBD [3]. However, even in these latter 
patients, the neoplastic tissue is massively infiltrated with 
immune cells, including T cells, natural killer (NK) cells 
and macrophages cells, which can either foster or inhibit 
the survival and growth of CRC cells, mostly through the 
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production of cytokines [4]. Additional protumorigenic 
signals originate from other cells present in the tumor 
tissue, such as tumor-associated macrophages and 
cancer-associated fibroblasts, whose functions are 
under the control of factors secreted by neoplastic cells, 
immune cells and stromal cells [5]. 
Interleukin-34 (IL-34) is a cytokine produced by a 
wide range of cells, including macrophages, endothelial 
cells, fibroblasts, neurons and epithelial cells and is 
constitutively expressed in adult human tissues, such as 
heart, brain, liver, spleen, thymus, testis, ovary, prostate, 
small intestine and colon [6–9]. IL-34 shares no apparent 
sequence homology with macrophage co type lony-
stimulating factor (M-CSF-1; also known as CSF-1) 
but its biological activity is mediated by interaction 
with the homodimeric M-CSF receptor 1 (M-CSFR-1; 
also known as CFS-1R or FMS) [10, 11]. M-CSFR-1 is 
mainly expressed on cell surface of macrophages and to 
a lesser extent by non-immune cells, such as trophoblasts, 
osteoclasts, smooth muscle cells and neurons [12–14]. 
IL-34/M-CSFR-1 signaling regulates myeloid cell 
differentiation, proliferation and survival and enhances 
secretion of pro-inflammatory cytokines and chemokines 
in various systems [12, 15–18]. A second uncovered 
receptor of IL-34, PTP-ζ, has been recently described [19].
Elevated levels of IL-34 are detectable in patients 
with various types of cancers, such as blood, brain, breast, 
eye, head and neck, lung, ovarian and skin cancer, and it 
has been demonstrated that IL-34 expression is associated 
with the progression of such tumours [6, 20–24]. There 
is also evidence that IL-34 plays a role in tumorigenesis 
given its ability to stimulate endothelial cell proliferation, 
vascular cord formation and recruitment of macrophages 
into the tumor tissue [20, 25]. However, the role of IL-34 
in sporadic CRC is unknown. We here investigated the 
expression and functional role of IL-34 in CRC.
RESULTS
Sporadic colorectal cancer over-expresses IL-34
To examine if IL-34 expression is differently 
regulated during CRC, total RNA was extracted from 
paired colonic samples of non-tumoral and tumoral 
areas of patients with sporadic CRC and analyzed by 
real-time PCR. Tumoral samples expressed higher IL-34 
RNA levels than non-tumoral samples of the same CRC 
patients (Figure 1A). Western blotting of total proteins 
extracted from freshly obtained samples and densitometry 
analysis of blots confirmed up-regulation of IL-34 in the 
tumoral samples (Figure 1B). Consistently, IL-34 protein 
level measured by ELISA was significantly increased 
in extracts of tumoral area than in those of non-tumoral 
area of CRC patients (Figure 1C). Immunohistochemistry 
analysis of CRC sections showed that IL-34 was mostly 
produced by cancer cells and to lesser extent by lamina 
propria mononuclear cells (LPMC) while staining of 
normal colonic sections revealed that IL-34 was weakly 
expressed by LPMC and virtually absent in epithelial cells 
(Figure 1D). 
To examine whether IL-34 production is regulated 
by inflammatory cytokines that are over-produced in CRC 
tissue [26–29], DLD-1 cells were stimulated with TNF-α, 
IL-6, IL-17A and IFN-γ and IL-34 secretion was evaluated 
by ELISA. In each of 3 independent experiments, all these 
cytokines enhanced IL-34 secretion (Table 1). 
Enhanced expression of M-CSFR-1 in CRC 
To begin to examine whether IL-34 controls CRC 
cell behavior, we analyzed expression of IL-34 receptors 
in paired colonic samples taken from tumoral and non-
tumoral areas of CRC patients. M-CSFR-1 expression 
quantitated by densitometry and normalized by β-actin 
expression was significantly increased in proteins 
extracted from tumoral areas as compared to samples of 
non-tumoral areas (Figure 2A). Immunohistochemical 
analysis confirmed such data and showed that CRC cells 
were strongly positive for this receptor (Figure 2B). 
Western blotting showed that PTP-z was detectable in all 
the samples with no apparent difference between tumoral 
and non-tumoral areas (Figure 2A). Immunohistochemical 
analysis showed that such a receptor was expressed 
by both epithelial cells and LPMC in non-tumoral and 
tumoral areas (Figure 2B). Consistently, both receptors 
were seen in HCT-116 and DLD-1, two CRC cell lines 
(Supplementary Figure 1). Altogether, these data indicate 
that CRC cells have the potential to functionally respond 
to locally-produced IL-34. 
IL-34 enhances CRC cell proliferation and cell 
invasion
Next, we investigated whether IL-34 controls 
CRC cell growth, survival and invasion. IL-34 enhanced 
DLD-1 and HT-29 cell growth, an effect that was mainly 
evident at a final concentration of 50 ng/ml (Figure 3A, 
Supplementary Figure 2A). In contrast, no significant 
change in the percentages of Annexin V (AV)/propidium 
iodide (PI)-positive cells was seen following stimulation 
of CRC cells with IL-34 (Figure 3B, Supplementary 
Figure 2B). Similarly, IL-34 did not significantly affect 
the fractions of AV/PI-positive cells induced by FAS 
Ligand or TNF-α (Figure 3C–3D). The proliferative effect 
of IL-34 appeared to be specific on CRC cells, as IL-6 but 
not IL-34 increased the growth of HCEC-1C, a normal 
colon epithelial cell line (Supplementary Figure 2C). 
Moreover, by using a matrigel invasion assay, we showed 
that IL-34 enhanced DLD-1 cell invasion (Figure 4). No 
significant change in cell proliferation and viability was 
seen following stimulation of DLD-1 cells with M-CSF-1 
(Figure 5A–5B). 
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Figure 1: Interleukin-34 (IL-34) RNA transcripts and protein are increased in sporadic colorectal cancer (CRC). 
(A) Paired colonic explants taken from non-tumoral (NT) and tumoral (T) areas of 12 patients with sporadic CRC were analyzed for IL-
34 RNA expression by real-time PCR and levels were normalized to β-actin. Each point represents the value of IL-34 mRNA in a single 
patient and horizontal bars indicate the median value. (B) Representative Western blots showing IL-34 and β-actin in total proteins extracted 
from paired non-tumoral (NT) and tumoral (T) areas of two patients with sporadic CRC. Bottom panels show the quantitative analysis of 
IL-34/β-actin ratio in samples taken from paired non-tumoral (NT) and tumoral (T) areas of 5 CRC patients as measured by densitometry 
scanning of Western blots. Values are expressed in arbitrary units (a.u.) and indicate mean ± SEM of all samples. (C) Quantitative analysis 
of IL-34 protein expression in paired colonic explants taken from the non-tumoral (NT) and tumoral (T) areas of 8 patients with sporadic 
CRC were measured by ELISA. Data were expressed as mean ± SEM of all samples. (D) Representative photomicrographs (100× original 
magnification) of IL-34-stained frozen sections of surgical specimens taken from non-tumoral (NT) and tumoral (T) areas of one patient 
with sporadic CRC. Staining with isotype control antibody is also shown. Right panel shows the number of IL-34-positive cells for high 
power field (hpf) of 8 separate experiments in which sections of 8 CRC patients were analyzed. Data are expressed as mean ± SEM.
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IL-34 stimulates CRC cell proliferation via 
ERK1/2-dependent pathway 
In the subsequent studies, we explored the 
basic mechanism by which IL-34 regulates positively 
CRC cell growth. Initially, we examined whether 
IL-34 activates signalling pathways that control 
neoplastic cell proliferation. To this end, DLD-1 
cells were either left unstimulated or stimulated 
with IL-34 or TNF-α, IL-6 or IL-22, which were 
used as positive inducers of MAP Kinases, NF-
Kβ and STAT3 signalling respectively [30–34]. 
Table 1: IL-34 is induced by TNF-α, IL-6, IL-17A and IFN-γ in DLD-1 cancer cells
Experiment UNST TNF-α (20 ng/ml) IL-6  (50 ng/ml) IL-17A (20 ng/ml) IFN-γ (100 ng/ml)
1° 44,6 114,8 81,9 82,8 119
2° 27,1 53,9 54,9 57 143
3° 28,1 51,9 40,5 54,9 155
DLD-1 cells were stimulated with TNF-α (20 ng/ml), IL-6 (50 ng/ml), IL-17 A (20 ng/ml) and IFN-γ (100 ng/ml). After 
48 hours, cell-free culture supernatants were collected and analyzed by ELISA. Data are expressed as pg/ml and indicate the 
values of IL-34 measured in supernatants of 3 independent experiments
Figure 2: Macrophage colony-stimulating factor -1 receptor (M-CSFR-1) but not Receptor-type tyrosine-protein 
phosphatase zeta (PTP-z) is increased in sporadic colorectal cancer (CRC). (A) Representative Western blots showing 
M-CSFR-1, PTP-z and β-actin in total proteins extracted from paired non-tumoral (NT) and tumoral (T) areas of 2 patients with sporadic 
CRC. Right panels show the quantitative analysis of M-CSFR-1/β-actin and PTP-z/β-actin ratio respectively in paired non-tumoral (NT) 
and tumoral (T) areas taken from 5 CRC patients as measured by densitometry scanning of Western blots. Values are expressed in arbitrary 
units (a.u.) and indicate mean ± SEM of all samples. (B) Representative photomicrographs (100x original magnification) of M-CSFR-1-
and PTP-z stained paraffin-embedded sections of surgical colonic samples taken from one control (CTR) and one patient with sporadic 
CRC. The figure is representative of 3 separate experiments in which sections taken from 4 CTR and 3 patients with CRC were analyzed 
for M-CSFR-1 and PTP-z. Staining with isotype control antibody is also shown. 
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IL-34 enhanced phosphorylation of both ERK1/2 and 
p38 MAP Kinases without affecting phosphorylation of 
STAT3 and NF-Kβ /p65 (Figure 6A). To test whether 
ERK1/2 and p38 activation mediates IL-34-driven 
DLD-1 cell growth, cells were pre-incubated with 
specific inhibitors of these two MAP Kinases prior to 
being stimulated with IL-34. Treatment of DLD-1 cells 
with PD98059, an inhibitor of ERK1/2, but not with 
SB202190, a p38 inhibitor, abrogated IL-34-induced 
DLD-1 cell proliferation (Figure 6B). 
Figure 3: Interleukin-34 (IL-34) induces CRC cell proliferation but does not affect cell death. (A) Serum-starved DLD-1 
cells were either left unstimulated (Unst) or stimulated with increasing doses of recombinant human IL-34 (25–100 ng/ml) for 48 hours. 
Cell proliferation was evaluated by flow cytometry and proliferation index was calculated with Modfit LT. Data indicate mean ± SEM of 4 
independent experiments. Right insets: representative dot-plots showing the percentages of CFSE- and/or PI-positive cells before and after 
IL-34 stimulation. (B) Serum-starved DLD-1 cells were either left unstimulated (Unst) or stimulated with increasing doses of recombinant 
human IL-34 (25–100 ng/ml) for 48 hours. Data indicate the percentage of cell death as assessed by flow cytometry analysis of AV and/or PI-
positive cells and are expressed as mean ± SEM of 4 experiments. (C) Serum-starved DLD-1 cells line were either left unstimulated (Unst) or 
stimulated with recombinant human IL-34 (50 ng/ml) and/or Fas Ligand (Fas L) (200 ng/ml) for 48 hours. The percentage of cell death was 
assessed by flow cytometry analysis of AV and/or PI-positive cells. Data indicate mean ± SEM of 4 independent experiments. (D) Serum-
starved DLD-1 cells were either left unstimulated (Unst) or stimulated with recombinant human IL-34 (50 ng/ml) and/or TNF-α (100 ng/ml) 
for 48 hours. The percentage of cell death was assessed by flow cytometry analysis of AV and/or PI-positive cells. Data indicate mean ± SEM 
of 4 independent experiments.
Oncotarget3437www.impactjournals.com/oncotarget
IL-34 knockdown with a specific antisense 
oligonucleotide reduces CRC cell growth
To confirm that CRC cell-derived IL-34 regulates 
positively CRC cell proliferation, we inhibited IL-
34 in HT-29 cells with a specific IL-34 antisense 
oligonucleotide. For these experiments, we selected HT-
29 cells as this cell line expresses elevated levels of IL-34 
(Figure 7A). Treatment of HT-29 cells with the specific 
IL-34 antisense oligonucleotide decreased IL-34 protein 
expression (Figure 7B) and phosphorylation of ERK1/2 
and ELK1, a down-stream target of ERK1/2 (Figure 7C). 
IL-34 knockdown was associated with a significant 
reduction of cell growth (Figure 7D) but no change in 
cell viability (Figure 7E). Finally, treatment of HT-29 
cells with IL-34 antisense oligonucleotide enhanced 
the susceptibility of cells to oxaliplatin (OXL)-induced 
death while cells were resistant to 5-Fluorouracile (5-FU) 
Figure 4: Interleukin-34 (IL-34) induces CRC cell invasion. DLD-1 cells (3 × 104) were seeded in Transwell inserts precoated 
with Matrigel, and either left unstimulated (Unst) or stimulated with IL-34 (50 ng/ml) or 10% fetal bovine serum (FBS) (used as positive 
control of invasion) for 48 hours. Data are expressed as mean ± SEM of three independent experiments. 
Figure 5: Macrophage colony-stimulating factor -1 (M-CSF-1) does not affect CRC cell growth and death. (A) Serum-
starved DLD-1 cells were either left unstimulated (Unst) or stimulated with increasing doses of recombinant human M-CSF-1 (25–100 ng/
ml) or IL-6 (50 ng/ml, used as a positive control) for 48 hours. Cell proliferation was evaluated with CFSE staining by flow cytometry. Data 
indicate mean ± SEM of four independent experiments. (B) Serum-starved DLD-1 cells were either left unstimulated (Unst) or stimulated 
with increasing doses of recombinant human M-CSF-1 (25–100 ng/ml) for 48 hours. The percentage of cell death was assessed by flow 
cytometry analysis and expressed as percentage of AV and/or PI-positive cells. Data are expressed as mean ± SEM of 6 independent 
experiments.
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and Irinotecan (CPT-11), regardless of whether IL-34 
expression was silenced (Figure 7F).
DISCUSSION
Although the exact sequence of events that sustain 
CRC growth remains poorly characterized, there is 
evidence that cytokines produced by immune cells and 
stromal cells exert proliferative effects on CRC cells [4, 
35]. On the other hand, CRC cells can produce additional 
factors that acting in a paracrine/autocrine manner expand 
further cell growth [36]. Identifying such molecules and 
the molecular mechanisms underlying CRC cell growth 
could help design novel therapeutic strategies for patients 
with advanced CRC. 
The present study was undertaken to examine the 
expression and functional role of IL-34 in human CRC. 
By using various assays, we initially showed that IL-
34 is constitutively expressed in the normal colon and 
its expression is increased in tumoral samples of CRC 
patients. Analysis of cell sources of IL-34 showed that 
both cancer cells and mononuclear cells infiltrating the 
tumoral tissue produce elevated levels of the cytokine. 
Normal colonic mucosa, adjacent to the tumoral area, 
expressed low levels of IL-34, thus suggesting that stimuli 
generated within the tumoral microenvironment can elicit 
IL-34 production. In this context, data of the present 
study indicate that cytokines over-produced by immune 
cells infiltrating the CRC tissue, such as TNF-α, IL-6, IL-
17A and IFN-γ [26–29], enhance IL-34 production. The 
fact that IL-34 expression was enhanced by IFN-γ could 
appear inconsistent with the notion that IFN-γ stimulates 
anti-tumor adaptive immune response. However, there 
is evidence that, in specific conditions IFN-γ is pro-
tumorigenic [29, 37]. 
We show also CRC cells express both M-CSFR-1 
and PTP-z, the two known IL-34 receptors, and, therefore, 
are potentially capable of responding to the cytokine. 
Indeed, stimulation of CRC cells with IL-34 resulted in 
enhanced cell growth and cell invasion, while the cytokine 
did not alter CRC cell viability. Treatment of CRC cells 
with M-CSF-1, another ligand of M-CSFR-1, associated 
with no change in cell growth and survival. These findings 
are in line with results of previous studies showing that 
IL-34 and M-CSF-1 exert non-redundant functions 
though they share a common receptor [10]. The divergent 
functions of these two cytokines could rely on their 
ability to differently bind and signal through the receptor 
Figure 6: Interleukin-34 (IL-34) induces CRC cell proliferation through an ERK1/2-dependent mechanism. (A) Serum-
starved DLD-1 cells were either left unstimulated (Unst) or stimulated with IL-34 (50 ng/ml), TNF-α (25 ng/ml), IL-6 (25 ng/ml), IL-22 
(25 ng/ml) for 15 minutes. Phosphorylated and total forms of the STAT3, NF-KB/p65 , ERK1/2, p38, and β-actin were evaluated by 
Western blotting. One of 4 independent experiments is shown. (B) Serum-starved DLD-1 cells were pre-incubated with either specific 
inhibitors of ERK1/2 and p38 (PD98059 and SB202190 respectively) or with Dimethyl sulfoxide (DMSO, vehicle) for 1 hour and then 
stimulated with IL-34 (50 ng/mL) for further 48 hours. Cell proliferation was evaluated by flow cytometry. Data indicate mean ± SEM of 
4 independent experiments.
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Figure 7: Knockdown of IL-34 with a specific antisense oligonucleotide decreases HT-29 cell proliferation and 
increases oxaliplatin-induced cell death. (A) IL-34 was evaluated in the human CRC cell lines DLD-1, HT-29 and HCT-116 by 
real-time PCR and levels were normalized to β-actin. (B) HT-29 cells were transfected with scrambled negative control oligonucleotide 
(SCR AS) or IL-34 antisense oligonucleotide (IL-34 AS) (both used at 2 µg/ml) for 48 hours. IL-34 and β-actin were analyzed by Western 
blotting. One of 4 independent experiments is shown. (C) HT-29 cells were transfected with either SCR AS or IL-34 AS (both used at 
2 µg/ml) for 72 hours. Phosphorylated and total forms of ERK1/2, ELK 1, IL-34 and β-actin were evaluated by Western blotting. One 
of 4 independent experiments is shown. (D) HT-29 cells were transfected with either SCR AS or IL-34 AS (both used at 2 µg/ml) for 72 
hours. Cell proliferation was evaluated by flow cytometry following staining with CFSE. Data indicate mean ± SEM of 4 independent 
experiments. (E) HT-29 cells were transfected with either SCR AS or IL-34 AS (both used at 2 µg/ml) for 72 hours. The percentage of cell 
death was assessed by flow cytometry. Data are indicated as percentage of AV and/or PI-positive cells and expressed as mean ± SEM of 4 
indipendent experiments. (F) HT-29 cells were transfected with either SCR AS or IL-34 AS (both used at 2 µg/ml) for 24 hours and then 
stimulated with 5-Fluorouracile (5-FU), Oxaliplatin (OXL) and Irinotecan (CPT-11) (all used 100 µM) or DMSO (vehicle) for further 24 
hours. Data are expressed as mean ± SEM of 4 independent experiments.
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as previous studies showed that IL-34 is more powerful 
than M-CSF-1 in triggering M-CSFR-1 activation [38]. 
The fact that CRC cells express both IL-34 and IL-
34 receptors raises the possibility that IL-34 acts in an 
autocrine and/or paracrine manner to regulate CRC cell 
growth. This hypothesis is supported by the demonstration 
that knockdown of IL-34 with a specific antisense 
oligonucleotide in HT-29 cells reduced cell growth 
without affecting cell apoptosis/necrosis. Moreover, IL-
34 knockdown enhanced the susceptibility of CRC cells 
to OXL-induced death. These results are consistent with 
studies in lung cancer showing that IL-34, produced 
during chemotherapy, enhances cancer cell survival [22].
Evaluation of the intracellular pathways sustaining 
CRC cell growth revealed that IL-34 activates ERK1/2 
and p38 MAP kinases. However, pharmacological 
inhibition of ERK1/2 but not of p38 abrogated the ability 
of IL-34 to enhance CRC cell growth. These findings 
are in line with the demonstration that M-CSFR-1 has 
a tyrosine kinase activity and interaction with IL-34 
induces the phosphorylation of a tyrosine residue of the 
receptor cytoplasmic domain and its homodimerisation, 
with the downstream effect of initiating a cascade of 
phosphorylation of other proteins, including ERK1/2 
[10–12]. 
Recent studies showed a positive correlation 
between IL-34 expression and tumor development. For 
example, IL-34 promotes osteoclastogenesis and appears 
to be involved in giant cell tumors of bone [6]. Initial 
evidence suggests the involvement of IL-34 in mammary 
cancer in which IL-34 levels have been associated with 
shorter survival and time to recurrence following cytotoxic 
therapies [24]. In such a neoplasia, as well as in other 
tumors (i.e. teratoma, hepatocellular carcinoma), the pro-
tumoral effect of IL-34 would be linked to the ability of 
the cytokine to promote the survival and the differentiation 
of type 2 macrophages [23, 25, 39, 40]. Data of the present 
study expand on these observations and indicate that IL-34 
can directly target cancer cells and stimulate intracellular 
pathways that positively regulate colon carcinogenesis. 
This does not however exclude the possibility that IL-34 
can control the function of additional cell types, which 
in turn sustain CRC cell proliferation. For instance, IL-
34 stimulates intestinal immune cells to make TNF-α and 
IL-6, two cytokines exerting proliferative effects on CRC 
cells, and has been involved in the suppressive function 
of regulatory T cells, a subset of T cells whose activity 
associates with the progression of cancer cells [18, 26, 41–
43]. Moreover, IL-34 facilitates polarization of memory T 
cells into Th17 cells, which enhance cancer cell growth in 
many organs [44].   
In conclusion, this is the first study showing up-
regulation of IL-34 in CRC and suggesting a role for this 
cytokine in the growth of CRC cells.
METHODS
Patients and samples
Paired tissue samples were taken from the tumoral 
area and the macroscopically and microscopically 
unaffected, adjacent colonic mucosa of 26 patients who 
underwent colon resection for sporadic CRC at the Tor 
Vergata University Hospital (Rome, Italy) or Fondazione 
IRCCS Cà Granda, Ospedale Maggiore Policlinico 
(Milan, Italy). All patients received neither radiotherapy 
nor chemotherapy prior to undergoing surgery.
Each patient who took part in the study gave written 
informed consent and the study protocol was approved 
by the local Ethics Committee (Tor Vergata University 
Hospital, Rome. Protocol number:171/16).
Intestinal epithelial cell lines
The human colon cancer cell lines DLD-1 
(phenotype: k-ras mutation G13D, p53 wild type), HT-
29 (phenotype: k-ras wild type, mutated p53) and HCT-
116 (phenotype: : k-ras mutation G13D, p53 wild type) 
were cultured in 25 cm2 plastic flasks and maintained at 
37°C in a humidified atmosphere of 5% CO
2
 in RPMI 
1640 or McCoy’s 5A (all from Lonza, Verviers, Belgium) 
supplemented with 10% fetal bovine serum (FBS), 
penicillin (P) (100 U/ml), streptomycin (S) (100 μg/ml) 
(all from Lonza). Human colon epithelial cells (HCEC-
1CT) were cultured in 25 cm2 plastic flasks and maintained 
at 37°C in a humidified atmosphere of 5% CO
2
 in medium 
ColoUpTm (Evercyte GmbH, Muthgasse, Vienna). 
To evaluate whether IL-34 or M-CSF-1 regulate 
cancer cell growth and viability, 2 × 105 DLD-1 cells, HT-
29 cells or HCEC-1CT cells were plated into each well of a 
6-wells plate and left to adhere. After 24 hours, cells were 
starved for 12 hours and then stimulated with recombinant 
human IL-34 or M-CSF-1 (both used at a final concentration 
of 25–100 ng/mL, R&D Systems, Inc. Minneapolis, MN, 
USA) or IL-6 (50 ng/ml, R&D Systems) in fresh medium 
containing 0,05% bovine serum albumin (BSA) (Sigma) 
for 48 hours. To evaluate if IL-34 synergizes with apoptotic 
stimuli, serum-starved DLD-1 cells were either left 
unstimulated or stimulated with recombinant human IL-
34 (50 ng/mL) in presence or absence of FasL (200 ng/ml, 
Enzo Life, Sciences, NY, USA) or TNF-α (100 ng/ml, R&D 
Systems) for 48 hours. At the end of cell culture, cell death 
was assessed by flow cytometry. 
To determine the factors that modulate IL-34 
expression, DLD-1 cells were either left unstimulated 
or stimulated with TNF-α (20 ng/ml), IL-6 (50 ng/ml), 
IL-17A (20 ng/ml, R&D Systems) or IFN-γ (100 ng/ml, 
Peprotech Ec Ltd,). After 48 hours, cell-free supernatants 
were analyzed by ELISA. To examine the molecular 
mechanism that controls the proliferative effect of IL-
34 on cancer cells, serum-starved DLD-1 cells were 
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either left unstimulated or stimulated with recombinant 
human IL-34 (50 ng/mL), TNF-α (25 ng/mL), IL-6 
(25 ng/mL) and IL-22 (25 ng/ml) for 15 minutes, then 
lysed and total extracts were analyzed for the content 
of both phosphorylated and total form of MAP kinases 
(ERK1/2, p38), NF-kB p65 and Stat3 by Western 
blotting. To evaluate the effect of MAP Kinase on IL-34-
induced cancer cell proliferation, serum-starved DLD-1 
cells were preincubated with PD98059 (50 µM, EMD 
Millipore Corporation, Billerica, MA, USA), a selective 
inhibitor of ERK1/2, or SB202190 , an inhibitor of p38 
(10 mol/L, EMD Millipore) or dimethyl sulfoxide 
(DMSO; vehicle, Sigma-Aldrich, Milan, Italy) for 1 
hour and then stimulated or not with IL-34 (50 ng/ml) 
for 48 hours. The specificity of both ERK1/2 and p38 
inhibitors has been previously verified [18]. At the end 
of cell culture, cell proliferation was assessed by flow 
cytometry. 
In additional experiments, HT-29 cells were either 
left untreated or transfected with a specific IL-34 antisense 
oligonucleotide or scrambled antisense oligonucleotide (both 
used a 2 µg/ml, Exiqon, Woburn, MA, USA) for 48–72 hours 
using Opti-MEM medium and Lipofectamine 3000 reagent 
(both from Life Technologies, Milan, Italy) according to the 
manufacturer’s instructions. At the end, cell viability and 
proliferation and ERK1/2 activation were evaluated. The 
efficiency of the transfection was determined by Western 
blotting. To evaluate the effect of IL-34 on chemotherapeutic 
agent-induced CRC cell death, HT-29 cells were transfected 
with the specific IL-34 antisense oligonucleotide or scrambled 
antisense oligonucleotide (both used a 2 µg/ml, Exiqon,) for 
24 hours and then stimulated with 5-FU, OXL or CPT-11 
(all used 100 µM, Sigma) or DMSO (vehicle) for further 
24 hours. At the end, cell viability was evaluated by flow 
cytometry. 
Analysis and quantification of cell proliferation 
and death
Cell proliferation was assessed by flow cytometry 
using carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Molecular Probes, Life Technologies), which 
covalently binds cell components to yield a fluorescence 
that is divided equally between daughter cells at each 
division. 
Briefly, starved DLD-1 or HT-29 cells were 
incubated with CFSE according to the manufacturer’s 
instructions. After 30 min, the medium was removed 
and fresh medium was added for the indicated time 
points. At the end, cells were collected, washed twice 
with PBS, and then incubated with PI (5 mg/ml, 
Life Technologies) for 15 min at 4°C in the dark. 
CFSE- and/or PI-positive cells were determined by flow 
cytometry (FACSVerse BD Biosciences, San Jose, CA, 
USA) and the data were analyzed using ModFit LT 5.0 
(Verity Software House, Inc., Topsham, ME, USA) and 
expressed as proliferation index relative to unstimulated 
conditions. 
To score cell death, DLD-1 or HT-29 cells, left 
untreated or stimulated as described above for the indicated 
time points, were washed in PBS, stained with FITC-AV 
(1:100 final dilution, Immunotools, Friesoyte, Germany) 
according to the manufacturer’s instructions and incubated 
with 5 mg/ml PI (Life Technologies) for 20 min at 4°C. 
Then, the fluorescence was measured by flow cytometry 
using FL-1 and FL-2 channels of FACSVerse (BD 
Biosciences) flow cytometer. Viable cells were considered 
as AV-/PI-cells, apoptotic cells as AV+/PI-cells, whereas 
secondary necrotic cells were characterized by AV+/PI+ 
staining. Data are expressed as percentage of cell death.
Cell invasion assay
To evaluate if IL-34 promotes CRC cell invasion, 
transwell inserts (Corning, Inc., Corning, NY, USA) 
were precoated with Matrigel matrix (BD Biosciences, 
Franklin Lakes, NJ, USA) mixed 1:1 with RMPI 1640 
(Lonza) at 37°C for 6 hours. DLD-1 cells were trypsinized 
and plated into the upper chambers at a concentration of 
3 × 104 cells/100 µl in serum-free RPMI 1640 with 0,05% 
of BSA (Sigma). The lower chambers were filled with 
800 µL RPMI-1640 medium containing 0,05% BSA and 
IL-34 (50 ng/ml) or 10% FBS (Lonza), used as positive 
control of matrigel-invasion. Cells were incubated in 
a humidified incubator at 37°C with 5% CO2 for 48 h. 
Afterwards, cells were fixed in 4% paraformaldehyde 
(Sigma) for 2 min at room temperature, permeabilized with 
100% of Methanol (Sigma) for 20 min at room temperature, 
and stained with crystal violet (Sigma). The non-invading 
cells that remained on the upper surface of the membrane 
were removed by scraping while the invaded cells were 
counted using an inverted microscope at a magnification 
400X in at least 8 randomly selected fields using IAS 2000 
System (Delta Sistemi, Rome, Italy).
Real-time PCR
A constant amount of RNA (0,5 μg/sample) was 
retro-transcribed into complementary DNA (cDNA) 
and then 1 μl of cDNA/sample was amplified using 
the following conditions: denaturation 1 minute at 
95°C; annealing 30 seconds, at 60°C for β-Actin and 
IL-34 followed by 30 seconds of extension at 72°C. 
Primer sequences: IL-34: forward, 5′- ACAGGAG 
CCGACTTCAGTAC-3′ and reverse, 5′- ACCAAGAC 
CCACAGATACCG-3′; β-actin: forward, 5′-AAGATGACC 
CAGATCATGTTTGAGACC-3′ and reverse 5′-AGCCAG 
TCCAGACGCAGGAT-3′. mRNA expression was 
calculated relative to the housekeeping β-Actin gene on 
the base of the Δ ΔCt algorithm.
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Total protein extraction and Western blotting
Paired tissue samples of tumoral and non-
tumoral areas and colon cancer cells were lysed on 
ice in buffer containing 10 mM HEPES (pH 7.9), 
10 mM KCl, 0.1 mM EDTA, 0.2 mM EGTA and 0.5% 
Nonidet P40 supplemented with 1 mM dithiothreitol, 
10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM Na3VO4 and 1 mM 
NaF. Lysates were clarified by centrifugation at 4°C, 
12.000 × g for 30 minutes, and separated on 10% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis. IL-
34, M-CSFR-1, PTP-z, phosphorylated (p) ERK1/2, ELK-
1, p-p38, p-STAT3 and p-NF-kB p65 were detected using 
the following antibodies: mouse anti human IL-34 (1:1000 
Abcam, Cambridge, UK), rabbit anti-human M-CSFR-1 
(1:500 Novus Biological, Littleton, CO, USA), rabbit 
anti-human PTP-z (1:1000 Abcam), mouse anti-human 
p-ERK 1/2 (1:500 Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA), mouse anti-human p-ELK 1 (1:500 Santa 
Cruz Biotechnology, Inc., Dallas, TX, USA), rabbit anti-
human p-p38 (1:1000 EMD Millipore Corporation), rabbit 
anti human p-STAT3 Tyr705 (Cell Signaling, Danvers, 
MA, USA), rabbit anti human p-NF-κB/p65 Ser536 (Cell 
Signaling), respectively, followed by horseradish peroxidase–
conjugated secondary IgG monoclonal antibodies (all used 
at 1:20000 final dilution, Dako, Milan, Italy). The reaction 
was detected with a sensitive enhanced chemiluminescence 
kit (Pierce, Rockford, IL, USA). After the analysis, blots were 
stripped and incubated with the following internal loading 
controls: mouse anti-human β-actin antibody (final dilution 
1:5000 Sigma-Aldrich), rabbit anti-human total ERK1/2 
(1:500, Santa Cruz Biotechnology), mouse anti-human 
total p38, rabbit anti- human NF-κB/p65 and mouse anti-
human total STAT3 (at 1:500, Santa Cruz Biotechnology) 
followed by horseradish peroxidase–conjugated secondary 
IgG monoclonal antibodies (all used at 1:20000 final 
dilution, Dako). 
Immunohistochemistry 
Immunohistochemistry was performed on 
archival frozen sections of paired tumoral and non-
tumoral samples of 8 CRC patients. Freshly obtained 
samples were embedded in a cryostat mounting medium 
(Neg–50 Frozen Section Medium, Thermo Scientific, 
Langenselbold, Germany), snap frozen and stored at 
–80°C. Six μm-thickened sections were mounted onto 
superfrost plus glass slides (Thermo Scientific) and fixed 
in 4% neutral buffered formalin for 10 minutes at room 
temperature and then in increasing ethanol solutions. After 
washing in Tris Buffered Saline, endogenous peroxidase 
activity was quenched with 3% H
2
0
2
 diluted in methanol 
for 10 minutes at room temperature. The slides were 
incubated with a mouse monoclonal antibody directed 
against human IL-34 (final dilution 1:50000, Abcam, 
Cambridge, UK) at room temperature for 1 hour followed 
by a biotin-free HRP-polymer detection technology 
(Ultravision Detection System, Thermo Scientific, 
Waltham, MA, USA) with 3,3′diaminobenzidine (DAB) 
as a chromogen (Dako). The sections were counterstained 
with haematoxylin, dehydrated and mounted. Isotype 
control IgG-stained sections were prepared under identical 
immunohistochemical conditions as described above, 
replacing the primary antibody with a purified mouse 
normal IgG control antibody (R&D Systems). The IL-34-
positive cells were counted in at least 6 fields per section 
using IAS 2000 System (Delta Sistemi, Rome, Italy) and 
expressed as number of cells for high power field (hpf). 
Moreover, immunohistochemistry was performed on 
formalin-fixed paraffin-embedded sections of non-tumoral 
and tumoral samples of 6 CRC patients. The sections were 
deparaffinized and dehydrated through xylene and ethanol 
and the antigen retrieval was performed in Tris EDTA 
citrate buffer (pH 7.8) for 30 minutes in thermostatic 
bath at 98°C (Dako). Immunohistochemical staining was 
performed using a rabbit monoclonal antibody directed 
against human M-CSFR-1 (final concentration 1:200, 
Novus Biological) or rabbit anti-human PTP-z (1:100 
Abcam) at room temperature for 1 hour followed by a 
biotin-free HRP-polymer detection technology with  DAB 
as a chromogen (MACH 4 Universal HRP-Polymer Kit, 
Biocare Medical). The sections were counterstained with 
haematoxylin, dehydrated and mounted. Isotype control 
IgG-stained sections were prepared under identical 
immunohistochemical conditions as described above, 
replacing the primary antibody with a purified mouse or 
rabbit normal IgG control antibody.
Enzyme-linked immunosorbent assay (ELISA)
Human IL-34 was measured using a sensitive 
commercial ELISA kit (R&D Systems) according to the 
Manufacturer’s instructions. 
Statistical analysis
Differences between groups were compared using 
the Student’s t-test and Wilcoxon test. All the analyses 
were performed using Graph-Pad 5 software. 
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